We have focused on developing our business through organic growth and by expanding through acquisitions. In 2018 AddLife took an important step toward expansion and growth. Through our largest acquisition to date, Austrian Biomedica, we opened the door to Europe. The four other acquisitions completed during the year further strengthened the company within the prioritized niche areas. Together, the five acquisitions for the year are expected to add annual sales of about SEK 750 million.
AddLife owns and develops companies that enhance quality of life, reduce patient suffering and increase social benefit. To achieve this vision, we offer our subsidiaries competitive solutions that meet both the short-term and long-term needs of the customers. Below is our assessment of why AddLife has become a leading, value-generating operator in Life Science.
AddLife acquires and streamlines profitable market-leading niche companies in the field of Life Science. We will attain long-term profitable growth by continuously developing our business and organisation. AddLife combines the strength of a large enterprise with the dedication and business skills of an entrepreneur.
